Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 398.4 g/mol |
---|---|
Molecular Formula | C18H14N4O5S |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 6 |
Exact Mass | 398.06849073 g/mol |
Monoisotopic Mass | 398.06849073 g/mol |
Topological Polar Surface Area | 146 A^2 |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 804 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 6 | |
---|---|
Drug Name | Azulfidine |
PubMed Health | Salicylate (Oral route, Rectal route) |
Drug Classes | Antirheumatic, Gastrointestinal Agent |
Drug Label | AZULFIDINE EN-tabs Tablets contain sulfasalazine, formulated in a delayed release tablet (enteric-coated), 500 mg, for oral administration.AZULFIDINE EN-tabs Tablets are film coated with cellulose acetate phthalate to retard disintegration of the tab... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Suspension |
Route | Oral |
Strength | 500mg; 250mg/5ml |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
2 of 6 | |
---|---|
Drug Name | Azulfidine en-tabs |
PubMed Health | Sulfasalazine (By mouth) |
Drug Label | AZULFIDINE EN-tabs Tablets contain sulfasalazine, formulated in a delayed release tablet (enteric-coated), 500 mg, for oral administration.AZULFIDINE EN-tabs Tablets are film coated with cellulose acetate phthalate to retard disintegration of the tab... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Tablet, delayed release |
Route | oral; Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Pharmacia Upjohn; Pharmacia And Upjohn |
3 of 6 | |
---|---|
Drug Name | Sulfasalazine |
Drug Label | Sulfasalazine Tablets USP, 500 mg for Oral AdministrationTherapeutic classification: Anti-inflammatory agent.Chemical designation: 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid.Chemical Structure:The molecular weight of sulfasalazine is 398.39.... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Tablet, delayed release |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vintage Pharms; Watson Labs |
4 of 6 | |
---|---|
Drug Name | Azulfidine |
PubMed Health | Salicylate (Oral route, Rectal route) |
Drug Classes | Antirheumatic, Gastrointestinal Agent |
Drug Label | AZULFIDINE EN-tabs Tablets contain sulfasalazine, formulated in a delayed release tablet (enteric-coated), 500 mg, for oral administration.AZULFIDINE EN-tabs Tablets are film coated with cellulose acetate phthalate to retard disintegration of the tab... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Suspension |
Route | Oral |
Strength | 500mg; 250mg/5ml |
Market Status | Prescription |
Company | Pharmacia And Upjohn |
5 of 6 | |
---|---|
Drug Name | Azulfidine en-tabs |
PubMed Health | Sulfasalazine (By mouth) |
Drug Label | AZULFIDINE EN-tabs Tablets contain sulfasalazine, formulated in a delayed release tablet (enteric-coated), 500 mg, for oral administration.AZULFIDINE EN-tabs Tablets are film coated with cellulose acetate phthalate to retard disintegration of the tab... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Tablet, delayed release |
Route | oral; Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Pharmacia Upjohn; Pharmacia And Upjohn |
6 of 6 | |
---|---|
Drug Name | Sulfasalazine |
Drug Label | Sulfasalazine Tablets USP, 500 mg for Oral AdministrationTherapeutic classification: Anti-inflammatory agent.Chemical designation: 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid.Chemical Structure:The molecular weight of sulfasalazine is 398.39.... |
Active Ingredient | Sulfasalazine |
Dosage Form | Tablet; Tablet, delayed release |
Route | Oral |
Strength | 500mg |
Market Status | Prescription |
Company | Vintage Pharms; Watson Labs |
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6489
Submission : 1986-07-17
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22238
Submission : 2008-11-24
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14724
Submission : 2000-02-23
Status : Inactive
Type : II
Certificate Number : R1-CEP 2002-088 - Rev 02
Issue Date : 2015-03-20
Type : Chemical
Substance Number : 863
Status : Valid
Registration Number : 306MF10016
Registrant's Address : Waisha Road 99# Jiaojiang Taizhou City, Zhejiang China
Initial Date of Registration : 2024-01-24
Latest Date of Registration :
Registrant Name : Medica Korea Co., Ltd.
Registration Date : 2012-02-24
Registration Number : 20091224-105-F-46-02(1)
Manufacturer Name : Zhejiang Jizhou Pharmaceutical Co., Ltd.
Manufacturer Address : 99 waisha Road, Jiaojiang District, Taizhou City, Zhejiang province, 318000, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14751
Submission : 2000-03-08
Status : Inactive
Type : II
Registrant Name : Hanlim Pharmaceutical Co., Ltd.
Registration Date : 2009-12-24
Registration Number : 20091224-105-F-46-02
Manufacturer Name : Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Manufacturer Address : 99 waisha Road, Jiaojiang District, Taizhou City, Zhejiang province, 318000, China
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11163
Submission : 1994-10-26
Status : Inactive
Type : II
Certificate Number : R1-CEP 2004-278 - Rev 02
Issue Date : 2017-12-20
Type : Chemical
Substance Number : 863
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14688
Submission : 2000-01-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8886
Submission : 1990-12-10
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5145
Submission : 1983-10-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7242
Submission : 1987-11-09
Status : Inactive
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
RLD : No
TE Code :
Brand Name : SULFASALAZINE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 84964
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : SULFASALAZINE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 85828
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : SULFASALAZINE
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 500MG
Approval Date : 1983-05-24
Application Number : 88052
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : SULFASALAZINE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 80197
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : SULFASALAZINE
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 500MG
Approval Date : 2002-01-11
Application Number : 75339
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : AZULFIDINE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 7073
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : Yes
TE Code : AB
Brand Name : AZULFIDINE EN-TABS
Dosage Form : TABLET, DELAYED RELEASE;ORAL
Dosage Strength : 500MG
Approval Date : 1983-04-06
Application Number : 7073
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : No
TE Code :
Brand Name : AZULFIDINE
Dosage Form : SUSPENSION;ORAL
Dosage Strength : 250MG/5ML
Approval Date : 1982-01-01
Application Number : 18605
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : S.A.S.-500
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1982-01-01
Application Number : 83450
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : SULFASALAZINE
Dosage Form : TABLET;ORAL
Dosage Strength : 500MG
Approval Date : 1987-10-19
Application Number : 89590
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Regulatory Info :
Registration Country : Sweden
Brand Name : Salazopyrin
Dosage Form : TABLET
Dosage Strength : 500 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Salazopyrin
Dosage Form : TABLET
Dosage Strength : 500 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Salazopyrin
Dosage Form : SUPPOSITORY
Dosage Strength : 500 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : A Salazopyrin
Dosage Form : GASTRO
Dosage Strength : 500 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Salazopyrin En
Dosage Form : Sulfasalazine 500Mg 100 Unita' Oral Use
Dosage Strength : 100 cpr gastrores 500 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Salazopyrin A
Dosage Form : Enteric Tablet
Dosage Strength : 500 mg
Packaging : Box
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Salazopyrin
Dosage Form : Tabl
Dosage Strength : 0.5g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Salazopyrin EN
Dosage Form : Drag
Dosage Strength : 0.5g
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Salazopyrina
Dosage Form : TABLET
Dosage Strength : 500 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Sulfasalazine 2care4
Dosage Form : GASTRO
Dosage Strength : 500 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : SALAZOPYRIN TAB 500MG
Dosage Form : TABLET
Dosage Strength : 500MG
Packaging : 100
Approval Date :
Application Number : 2064480
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : SALAZOPYRIN EN-TABS 500 MG
Dosage Form : TABLET (ENTERIC-COATED)
Dosage Strength : 500MG
Packaging : 100/300
Approval Date :
Application Number : 2064472
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PMS-SULFASALAZINE-E.C. TAB 500MG
Dosage Form : TABLET (ENTERIC-COATED)
Dosage Strength : 500MG
Packaging : 100/500
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PMS-SULFASALAZINE 500MG/TAB USP
Dosage Form : TABLET
Dosage Strength : 500MG
Packaging : 100/500
Approval Date :
Application Number :
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PMS-SULFASALAZINE-E.C. TAB 500MG
Dosage Form : TABLET (ENTERIC-COATED)
Dosage Strength : 500MG
Packaging : 100/500
Approval Date :
Application Number : 598488
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PMS-SULFASALAZINE 500MG/TAB USP
Dosage Form : TABLET
Dosage Strength : 500MG
Packaging : 100/500
Approval Date :
Application Number : 598461
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Australia
Brand Name : Pyralin EN
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Salazopyrin-EN
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Salazopyrin
Dosage Form : tablet
Dosage Strength : 500 mg
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Salazopyrin
Dosage Form : tablet
Dosage Strength : 500 mg
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Pyralin EN
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Salazopyrin-EN
Dosage Form :
Dosage Strength :
Packaging : 100
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
81
PharmaCompass offers a list of Sulfasalazine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sulfasalazine manufacturer or Sulfasalazine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sulfasalazine manufacturer or Sulfasalazine supplier.
PharmaCompass also assists you with knowing the Sulfasalazine API Price utilized in the formulation of products. Sulfasalazine API Price is not always fixed or binding as the Sulfasalazine Price is obtained through a variety of data sources. The Sulfasalazine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Disalazin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Disalazin, including repackagers and relabelers. The FDA regulates Disalazin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Disalazin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Disalazin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Disalazin supplier is an individual or a company that provides Disalazin active pharmaceutical ingredient (API) or Disalazin finished formulations upon request. The Disalazin suppliers may include Disalazin API manufacturers, exporters, distributors and traders.
click here to find a list of Disalazin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Disalazin DMF (Drug Master File) is a document detailing the whole manufacturing process of Disalazin active pharmaceutical ingredient (API) in detail. Different forms of Disalazin DMFs exist exist since differing nations have different regulations, such as Disalazin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Disalazin DMF submitted to regulatory agencies in the US is known as a USDMF. Disalazin USDMF includes data on Disalazin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Disalazin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Disalazin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Disalazin Drug Master File in Japan (Disalazin JDMF) empowers Disalazin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Disalazin JDMF during the approval evaluation for pharmaceutical products. At the time of Disalazin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Disalazin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Disalazin Drug Master File in Korea (Disalazin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Disalazin. The MFDS reviews the Disalazin KDMF as part of the drug registration process and uses the information provided in the Disalazin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Disalazin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Disalazin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Disalazin suppliers with KDMF on PharmaCompass.
A Disalazin CEP of the European Pharmacopoeia monograph is often referred to as a Disalazin Certificate of Suitability (COS). The purpose of a Disalazin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Disalazin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Disalazin to their clients by showing that a Disalazin CEP has been issued for it. The manufacturer submits a Disalazin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Disalazin CEP holder for the record. Additionally, the data presented in the Disalazin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Disalazin DMF.
A Disalazin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Disalazin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Disalazin suppliers with CEP (COS) on PharmaCompass.
A Disalazin written confirmation (Disalazin WC) is an official document issued by a regulatory agency to a Disalazin manufacturer, verifying that the manufacturing facility of a Disalazin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Disalazin APIs or Disalazin finished pharmaceutical products to another nation, regulatory agencies frequently require a Disalazin WC (written confirmation) as part of the regulatory process.
click here to find a list of Disalazin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Disalazin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Disalazin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Disalazin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Disalazin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Disalazin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Disalazin suppliers with NDC on PharmaCompass.
Disalazin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Disalazin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Disalazin GMP manufacturer or Disalazin GMP API supplier for your needs.
A Disalazin CoA (Certificate of Analysis) is a formal document that attests to Disalazin's compliance with Disalazin specifications and serves as a tool for batch-level quality control.
Disalazin CoA mostly includes findings from lab analyses of a specific batch. For each Disalazin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Disalazin may be tested according to a variety of international standards, such as European Pharmacopoeia (Disalazin EP), Disalazin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Disalazin USP).